Galecto is a Swedish company founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company builds on more than 10 years of research into galectins and galectin modulators, which combined with a strong patent estate gives Galecto a unique platform.

The company develops galectin modulators for the treatment of severe diseases, including fibrosis and cancer.

Galecto Tel: (+45) 70 70 52 10